DRG Epidemiology’s coverage of pulmonary hypertension (PH) comprises epidemiological estimates of key patient populations in the Americas. We report the prevalence of PH for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of ten years for the pharmaceutical markets we cover in this report. In addition to forecasting prevalent patient populations, we forecast the number of drug-treatment opportunities in specific lines of therapy.
DRG Epidemiology’s PH forecast will answer the following questions:
- How many people will be diagnosed with PH?
- How will GDP trends, demographic trends, such as population aging and improving life expectancy, affect the epidemiology of PH over the forecast period?
- Pulmonary Hypertension - Epidemiology - Epidemiology Dashboard
Author(s): Alison Isherwood, MSc, MRes, PhD
Alison Isherwood, B.Sc., M.Res., M.Sc., Ph.D. joined Decision Resources Group in 2008, as an Epidemiologist. Alison holds a B.Sc. in Medical Microbiology, Masters by Research in the Life Sciences and a M.Sc. in Epidemiology all from the University of Edinburgh. Prior to joining Decision Resources Inc., she was working on her Ph.D. in Molecular Virology, specializing on the severe acute respiratory syndrome (SARS) coronavirus, at the University of Reading. In her role at Decision Resources Group, Alison is currently an Epidemiology team lead as well as project managing custom epidemiology work in multiple therapy areas. Alison’s area of specialization at DRG is cancer, particularly breast cancer.